Senti Biosciences, Inc.

Senti Biosciences, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company developing next-generation cell and gene therapies powered by proprietary gene circuit technology, with a focus on oncology and other serious diseases. The company entered the public markets through a business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS), a blank-check company that completed its initial public offering in 2021 and was sponsored by Dynamics Special Purpose Holdings LLC. An amended current report on Form 8-K/A was filed with the SEC on December 10, 2021, during the pendency of the de-SPAC transaction, which ultimately closed in 2022. Sign up on SpacDesk for full filings, timeline data, and analytics on SNTI and the broader SPAC universe.